{
  "Study_ID": "EStudo da CBZ versus LEV (mudar depois)",
  "Other_Demographics": "Not specified",
  "Partial_Resolution_Percentage": "27.9% (19/68) of non-calcified lesions",
  "Praziquantel_Dose": "Not used",
  "Seizure_Reduction_Percentage": "91.8% (45/49) for CBZ group, 78% (39/50) for LEV group",
  "Follow_up_Duration_Months": "6",
  "Focal_Seizures_Percentage": "30.3% (30/99)",
  "Corticosteroid_Type": "Prednisolone",
  "Risk_of_Bias": "Moderate - open label but randomized with computer-generated numbers",
  "Control_Group_N": "Not applicable - comparative study between two treatments",
  "Total_Sample_Size": "99",
  "Albendazole_Dose": "15mg/kg/day for 14 days",
  "Complete_Resolution_Percentage": "61.8% (42/68) of non-calcified lesions",
  "Treatment_Duration_Days": "Minimum 6 months follow-up",
  "Elevated_Liver_Enzymes_Percentage": "Not reported",
  "Treatment_Type": "Carbamazepine vs Levetiracetam",
  "First_Author": "Santhosh AP",
  "Imaging_Schedule": "Baseline and follow-up",
  "Comments": "CBZ showed better seizure control trend compared to LEV but had more minor side effects. Cost was 3-5 times lower for CBZ compared to LEV.",
  "Male_Percentage": "74.7% (74/99)",
  "No_Change_Percentage": "12.3% (7/68) of non-calcified lesions",
  "Treatment_Group_N": "49 (Carbamazepine), 50 (Levetiracetam)",
  "Country": "India",
  "Headache_Percentage": "43.4% (43/99)",
  "Diagnostic_Criteria": "Del Brutto diagnostic criteria for NCC, drug naïve patients with NCC presenting with seizures",
  "last_modified": "2024-10-31T14:09:49.909854",
  "Female_Percentage": "25.3% (25/99)",
  "Year": "2023",
  "Cycle_Interval_Days": "Not applicable",
  "Antiepileptic_Drug": "Carbamazepine (4-6 mg/kg/day increased to 10 mg/kg/day) or Levetiracetam (10mg/kg/day increased to 20mg/kg/day)",
  "Number_of_Cycles": "1",
  "Other_AE": "CBZ: 34.6% (dizziness, drowsiness, skin rash, gait ataxia, weight gain); LEV: 4% (dizziness, drowsiness)",
  "Other_Symptoms": "None had encephalitis, raised intracranial pressure or focal deficits",
  "Age_Mean_SD": "25.06 ± 10.1 years (CBZ group: 22.51±8.9, LEV group: 27.56±10.7)",
  "Study_Design": "Open labelled randomized comparative monotherapy study"
}